Page 73 - Read Online

Bobronnikova Biomarker of metabolic disorders and cardiovascular remodeling

of patients, taking into account gender differences and 37 prospective cohort studies. BMJ 2006;332:73-8.
duration of comorbid pathology. 5. Blacher J, Staessen JA, Girerd X. Pulse pressure not mean pressure
determines cardiovascular risk in older hypertensive patients. Arch
In conclusion, chronic hyperglycemia and insulin 6. Intern Med 2000;160:1085-9.
Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de
resistance affected the cardiovascular remodeling Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S,
of the myocardium and blood vessels, which was Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-
mostly observed in the concomitant AH and type 2 DM Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm
patients. J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra
M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW,
This study makes it possible to assume that Gal- Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A,
Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä
3 is involved in the processes of insulin resistance K, Raz I, Schernthaner G, Volpe M, Wood D; Task Force on Diabetes
progression and cardiovascular remodeling in and Cardiovascular Diseases of the European Society of Cardiology
patients with isolated hypertension and patients with (ESC); European Association for the Study of Diabetes (EASD).
hypertension and type 2 DM. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases:
executive summary. The Task Force on Diabetes and Cardiovascular
In order to gain a clearer understanding of the Gal-3 Diseases of the European Society of Cardiology (ESC) and of the
role in the pathogenesis of hypertension and type 2 European Association for the Study of Diabetes (EASD). Eur Heart J
2007;28:88-136.
DM, the larger clinical trial needs to be conducted. 7. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C,
Perticone F. Continuous relation between left ventricular mass
Authors’ contributions and cardiovascular risk in essential hypertension. Hypertension
L. Bobronnikova contributed solely to this paper. 2000;35:580-6.
8. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left
Financial support and sponsorship 9. ventricular hypertrophy. Am Heart J 2001;141:334-41.
Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson
None. MG, Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident
heart failure in the community. J Am Coll Cardiol 2012;60:1249-56.
Conflicts of interest 10. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC,
van Gilst WH, Hillege HL, Bakker SJ, van der Harst P. The fibrosis
There are no conflicts of interest. marker galectin-3 and outcome in the general population. J Intern
Med 2012;272:55-64.
Patient consent 11. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian
All the patients signed an informed consent agreement A, Muntendam P, van Veldhuisen DJ, de Boer RA. Prognostic value
of changes in galectin-3 levels over time in patients with heart failure:
to participate in the research. data from CORONA and COACH. Circ Heart Fail 2013;6:219-26.
12. Barrow H, Rhodes JM, Yu LG. Simultaneous determination of
Ethics approval serum galectin-3 and -4 levels detects metastases in colorectal cancer
The study protocol was approved by the Local Ethics patients. Cell Oncol (Dordr) 2013;36:9-13.
Committee of the Kharkov National Medical University 13. Vereecken P, Awada A, Suciu S, Castro G, Morandini R, Litynska
A, Lienard D, Ezzedine K, Ghanem G, Heenen M. Evaluation of
and was performed in accordance to the Declaration the prognostic significance of serum galectin-3 in American Joint
of Helsinki. Committee on Cancer stage III and stage IV melanoma patients.
Melanoma Res 2009;19:316-20.
REFERENCES 14. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel
blood test for the evaluation and management of patients with heart
1. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, failure. Rev Cardiovasc Med 2011;12:200-10.
Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, 15. Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic
Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis N, Hsu DK, Liu FT, Lukic ML. Targeted disruption of the galectin-3
AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, gene results in decreased susceptibility to multiple low dose
Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ streptozotocin-induced diabetes in mice. Clin Immunol 2009;130:83-
ESC Guidelines for the management of arterial hypertension: the Task 8.
Force for the management of arterial hypertension of the European 16. Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD,
Society of Hypertension (ESH) and of the European Society of Milovanovic MZ, Nikolic IG, Zdravkovic NS, Djukic AL, Arsenijevic
Cardiology (ESC). J Hypertens 2013;31:281-357. NN, Lukic ML. Galectin-3 deficiency accelerates high-fat diet-
2. Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D’Agostino RB Sr, induced obesity and amplifies inflammation in adipose tissue and
Wilson PW, Savage PJ. Trends in cardiovascular complications of pancreatic islets. Diabetes 2013;62:1932-44.
diabetes. JAMA 2004;292:2495-9. 17. Saksida T, Nikolic I, Vujicic M, Nilsson UJ, Leffler H, Lukic ML,
3. Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart Stojanovic I, Stosic-Grujicic S. Galectin-3 deficiency protects
failure: molecular mechanisms. Heart Fail Clin 2012;8:609-17. pancreatic islet cells from cytokine-triggered apoptosis in vitro. J Cell
4. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart Physiol 2013;228:1568-76.
disease associated with diabetes in men and women: meta-analysis of 18. Darrow AL, Shohet RV, Maresh JG. Transcriptional analysis of the
66 Vessel Plus ¦ Volume 1 ¦ June 27, 2017